Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
Twitter Feed
-
UCB is committed to improving women’s bone health. We cannot wait to explore solutions with @WomenDeliver & our fellow advocates this June. https://t.co/LuCJbUlp38 https://t.co/3KCkA41BBw
— UCB News (@ucb_news) 20.05.2019 -
MEDIA: Nayzilam® nasal spray now approved by US FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy https://t.co/2sXsKAoW6l https://t.co/s9oO4dzjo6
— UCB News (@ucb_news) 20.05.2019 -
Are you interested in clinical studies but have some difficulties with the medical jargon? We publish some of our results in easy-to-understand language. Have a look at UCB Lay Summaries #ClinicalStudies #InspiredByPatients https://t.co/MJdrOzrJGG https:/
— UCB News (@ucb_news) 20.05.2019
